195 related articles for article (PubMed ID: 26425558)
1. Rituximab as Single Agent in Primary MALT Lymphoma of the Ocular Adnexa.
Annibali O; Chiodi F; Sarlo C; Cortes M; Quaranta-Leoni FM; Quattrocchi C; Bianchi A; Bonini S; Avvisati G
Biomed Res Int; 2015; 2015():895105. PubMed ID: 26425558
[TBL] [Abstract][Full Text] [Related]
2. Systemic Rituximab Immunotherapy in the Management of Primary Ocular Adnexal Lymphoma: Single Institution Experience.
Tuncer S; Tanyıldız B; Basaran M; Buyukbabani N; Dogan O
Curr Eye Res; 2015; 40(8):780-5. PubMed ID: 25247376
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of chemotherapy as a first-line treatment in patients with ocular adnexal MALT lymphoma].
Ning F; Ye J; Wei LQ; Li X; Wang JW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):912-6. PubMed ID: 22931653
[TBL] [Abstract][Full Text] [Related]
4. A case of conjunctival MALT lymphoma: successfully treated with solely extended rituximab therapy.
Celiker H; Toker E; Kaygusuz Atagunduz I
Int Ophthalmol; 2019 Mar; 39(3):687-691. PubMed ID: 29411260
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa.
Ferreri AJ; Ponzoni M; Martinelli G; Muti G; Guidoboni M; Dolcetti R; Doglioni C
Haematologica; 2005 Nov; 90(11):1578-9. PubMed ID: 16266908
[TBL] [Abstract][Full Text] [Related]
6. Favourable response to rituximab by an ocular adnexal primary lymphoma.
Luque Valentin-Fernandez ML; Alvarez Rodríguez F; Rodríguez Jiménez I
Arch Soc Esp Oftalmol; 2016 Nov; 91(11):539-542. PubMed ID: 27125186
[TBL] [Abstract][Full Text] [Related]
7. Ocular adnexal lymphoma-comparison of MALT lymphoma with other histological types.
Cahill M; Barnes C; Moriarty P; Daly P; Kennedy S
Br J Ophthalmol; 1999 Jun; 83(6):742-7. PubMed ID: 10340987
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic analysis of ocular adnexal lymphomas: extranodal marginal zone b-cell lymphoma constitutes the vast majority of ocular lymphomas among Koreans and affects younger patients.
Cho EY; Han JJ; Ree HJ; Ko YH; Kang YK; Ahn HS; Ahn SD; Park CJ; Huh J
Am J Hematol; 2003 Jun; 73(2):87-96. PubMed ID: 12749009
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics of 95 patients with ocular adnexal and uveal lymphoma: treatment outcomes in extranodal marginal zone subtype.
Portell CA; Aronow ME; Rybicki LA; Macklis R; Singh AD; Sweetenham JW
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):203-10. PubMed ID: 24417911
[TBL] [Abstract][Full Text] [Related]
10. Rituximab and chlorambucil as first-line treatment for low-grade ocular adnexal lymphomas.
Rigacci L; Nassi L; Puccioni M; Mappa S; Polito E; Dal Pozzo S; Alterini R; Carrai V; Puccini B; Bosi A
Ann Hematol; 2007 Aug; 86(8):565-8. PubMed ID: 17483948
[TBL] [Abstract][Full Text] [Related]
11. [Extranodal marginal zone lymphoma of the ocular adnexa].
Møller A; Specht L; Toft PB; Sjø LD
Ugeskr Laeger; 2008 Nov; 170(45):3660-3. PubMed ID: 18986616
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
Salar A; Domingo-Domenech E; Estany C; Canales MA; Gallardo F; Servitje O; Fraile G; Montalbán C
Cancer; 2009 Nov; 115(22):5210-7. PubMed ID: 19672998
[TBL] [Abstract][Full Text] [Related]
13. Treating synchronous bilateral ocular adnexal marginal zone lymphoma: the consortium for improving survival of lymphoma study.
Oh SY; Kim WS; Kang HJ; Lee JH; Huh SJ; Kim SJ; Yoon DH; Hong JY; Lee WS; Kim HJ; Won JH; Park BB; Lee SI; Suh C
Ann Hematol; 2018 Oct; 97(10):1851-1857. PubMed ID: 29947974
[TBL] [Abstract][Full Text] [Related]
14. Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions.
Chanudet E; Zhou Y; Bacon CM; Wotherspoon AC; Müller-Hermelink HK; Adam P; Dong HY; de Jong D; Li Y; Wei R; Gong X; Wu Q; Ranaldi R; Goteri G; Pileri SA; Ye H; Hamoudi RA; Liu H; Radford J; Du MQ
J Pathol; 2006 Jul; 209(3):344-51. PubMed ID: 16583361
[TBL] [Abstract][Full Text] [Related]
15. [The preliminary observation of intralesional rituximab administration in primary ocular adnexal mucosa-associated lymphoid tissue lymphoma].
Yang JP; Pang X; Zhang K; Wang LL; Zhu Y
Zhonghua Yan Ke Za Zhi; 2020 Nov; 56(11):839-845. PubMed ID: 33152842
[No Abstract] [Full Text] [Related]
16. Radiotherapy for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa: a multiinstitutional, retrospective review of 50 patients.
Uno T; Isobe K; Shikama N; Nishikawa A; Oguchi M; Ueno N; Itami J; Ohnishi H; Mikata A; Ito H
Cancer; 2003 Aug; 98(4):865-71. PubMed ID: 12910532
[TBL] [Abstract][Full Text] [Related]
17. Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue-type of the orbit and ocular adnexa.
Lee JL; Kim MK; Lee KH; Hyun MS; Chung HS; Kim DS; Shin SO; Cho HS; Bae SH; Ryoo HM
Ann Hematol; 2005 Jan; 84(1):13-8. PubMed ID: 15309523
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of primary ocular adnexal lymphoma treatment with intraorbital rituximab injections.
Savino G; Battendieri R; Gari M; Caputo CG; Laurenti L; Blasi MA
J Cancer Res Clin Oncol; 2013 Jul; 139(7):1251-5. PubMed ID: 23625184
[TBL] [Abstract][Full Text] [Related]
19. Rituximab immunotherapy for ocular adnexal lymphoma: clinicopathologic correlation with 5-year follow-up.
Sokol JA; Landau L; Lauer SA
Ophthalmic Plast Reconstr Surg; 2009; 25(4):322-4. PubMed ID: 19617799
[TBL] [Abstract][Full Text] [Related]
20. Clinical, histopathological, and immunogenetic analysis of ocular adnexal lymphoproliferative disorders: characterization of malt lymphoma and reactive lymphoid hyperplasia.
Mannami T; Yoshino T; Oshima K; Takase S; Kondo E; Ohara N; Nakagawa H; Ohtsuki H; Harada M; Akagi T
Mod Pathol; 2001 Jul; 14(7):641-9. PubMed ID: 11454995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
